Timing of quality of life improvements in psoriatic patients treated with different systemic therapies
- Autori: Pistone G.; Gurreri R.; Tilotta G.; Caruso P.; Curiale S.; Bongiorno M.R.
- Anno di pubblicazione: 2019
- Tipologia: Review essay (rassegna critica)
- OA Link: http://hdl.handle.net/10447/377050
Psoriasis impacts the quality of life (QoL) by disrupting overall health and social life. Thus, the use of a QoL evaluation item is crucial in assessing a therapeutic regimen. Also, faster improvements in QoL lead to better patient compliance, but very few studies compare psoriasis traditional and biologic therapies timing. To evaluate how much different systemic therapies improve disease severity and QoL, a retrospective analysis was performed on 56 patients. Subjects were administered different drugs and their vital statistics, psoriasis area severity index (PASI) and PSOdisk were collected at baseline and after 30 days. We found a moderate correlation between PASI and PSOdisk score with (r): .62. In terms of clinical scores improvement after 30 days, Ustekinumab turned out to be the fastest therapy available, while cyclosporine, among the systemic therapies available, appeared as highly competitive if not better than other biologic therapies.